Enterprise Value
2.261B
Cash
135.7M
Avg Qtr Burn
-15.63M
Short % of Float
13.90%
Insider Ownership
6.24%
Institutional Own.
46.86%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2b Data readout | ||
VK5211 (SARM) Details Muscle injury following hip fracture | Phase 2 Update | |
VK2735 (subQ dual agonist of GLP-1 and GIP receptors) Details Metabolic disorder, Obesity | Phase 2 Initiation | |
VK0214 (small molecule thyroid hormone receptor agonist) Details X-linked adrenoleukodystrophy | Phase 1b Update | |
VK2735 (Oral formulation) (dual agonist of GLP-1 and GIP receptors) Details Metabolic disorder | Phase 1 Data readout |